Is NCT03169959 results overdue?

Yes — results are overdue. Primary completion was 2017-08-03; the FDAAA-801 reporting deadline (2018-08-03) passed 2879 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT ID	NCT03169959 ↗
Sponsor	AstraZeneca (INDUSTRY)
Public issuer	ASTRAZENECA PLC — AZN (CIK 0000901832) best-effort name match, 95% conf — verify on EDGAR ↗
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-08-03 (ACTUAL)
Reporting deadline	2018-08-03 (completion + 365d)
Days overdue	2879
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `522abef7f1da151e…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03169959. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.